Curing Hepatitis C Is Associated With a Reduced Risk of Death

The costs rise particularly steeply for those who quickly progress to end-stage liver disease.

As kids get heavier, doctors are increasingly seeing pediatric cases of fatty liver disease.

Sovaldi (sofosbuvir) plus the new hep C drug ravidasvir cured 97 percent of those with a range of genotypes in a recent study.

Among those without cirrhosis, treating for an additional four weeks is unnecessary.

About one third of those in a global study of individuals hospitalized with cirrhosis had such infections.

Analysts say the market will reach $35 billion in the next few years.

For example: Hep C cures have meant fewer people to treat and fewer transmissions to potential patients.

This finding suggests the need for long-term follow-up.

Liver cancer development is strongly associated with hep B.